MedTrace Logo

Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant

NCT02723435 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-05-04

No results posted yet for this study

Summary

This phase 2 trial studies the side effects and how well midostaurin works in treating older patients with acute myeloid leukemia with change in genetic material post-hematopoietic cell transplantation. Midostaruin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving midostaruin post-transplant may improve patient outcomes.

Conditions

  • Acute Myeloid Leukemia With Gene Mutations
  • Adult Acute Myeloid Leukemia in Remission

Interventions

DRUG

Midostaurin

Given PO

Sponsors & Collaborators

Principal Investigators

  • David Iberri, MD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2018-04-30
Completion
2018-04-30
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02723435 on ClinicalTrials.gov